Strikingly, a single intracranial injection of IL13-zetakine CAR T cells into mice with orthotopic glioma xenografts led to a robust decrease in tumor burden and increased median overall survival from 35 to 40 days in control mice to 88 days in IL13-zetakine CAR T cell-treated mice. Here, IL13 is linked to glioma.